Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067286 | 0.90 | HCRTR1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL4877479 | 0.87 | HCRTR1 (0.44) | HCRTR1HCRTR2PDE3BPDE3AP2RY12 | |
| SCHEMBL4778123 | 0.83 | ROCK2 (0.38) | HCRTR2ROCK2HRH4FFAR4 | |
| SCHEMBL4793782 | 0.82 | HCRTR2 (0.42) | HCRTR1HCRTR2ROCK2HRH4FFAR4 | |
| SCHEMBL4773029 | 0.78 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL4771741 | 0.78 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL4794761 | 0.77 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL5067294 | 0.77 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL4768695 | 0.76 | HCRTR1 (0.73) | HCRTR1HCRTR2 | |
| SCHEMBL4791855 | 0.70 | HCRTR1 (0.42) | HCRTR1HCRTR2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | claimed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| WO-2006110626-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885ROCK2 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.